The pharmacological blockade of TRPML1 has been proposed as alternative approach to treat many diseases associated with aberrant TRPML1-mediated Ca2+ release, including cancer [76], lysosomal storage disorders [77,78] and inflammatory disorders [79]. The gene discussed is MCOLN1; the disease is lysosomal storage disease.